99 related articles for article (PubMed ID: 17357186)
1. The response of urological tumours to immunotherapy.
Gkialas I; Kalantzis A; Lykourinas M
J BUON; 2005; 10(3):329-36. PubMed ID: 17357186
[TBL] [Abstract][Full Text] [Related]
2. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy EF
Iowa Orthop J; 2006; 26():154-8. PubMed ID: 16789469
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
Lamm DL
Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319
[TBL] [Abstract][Full Text] [Related]
4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
5. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
[TBL] [Abstract][Full Text] [Related]
6. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
Joudi FN; Smith BJ; O'Donnell MA; Konety BR
J Urol; 2006 May; 175(5):1634-9; discussion 1639-40. PubMed ID: 16600718
[TBL] [Abstract][Full Text] [Related]
7. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
8. Engineering Opportunities in Cancer Immunotherapy: After Decades of Missteps and Delays, a Growing Immune-Oncology Market and Improved Cancer Treatment Outcomes Open New Prospects for Biomedical Engineers and Data Scientists.
Zaharoff DA
IEEE Pulse; 2018; 9(4):8-11. PubMed ID: 30028678
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
10. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited.
Decker WK; Safdar A
Cytokine Growth Factor Rev; 2009 Aug; 20(4):271-81. PubMed ID: 19656718
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
[TBL] [Abstract][Full Text] [Related]
12. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
Patard JJ; Chopin DK
Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
14. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
15. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
16. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
17. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
18. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous Remission of Metastatic Castration-Resistant Prostate Cancer: Coley's Toxin Revisited?
Choe A; Mutsaers A; Rodrigues G; Chin J; Leung S; Winquist E
Cureus; 2022 Dec; 14(12):e32505. PubMed ID: 36654621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
